% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • jsblvbjb jsblvbjb Nov 1, 2013 11:44 AM Flag

    Richard Kollender's next project?

    Nupathe, PATH, IMO, he's going to try to turn things around over there, where an NDA approval and drug launch is anything but reflected in the SP performance and value could be unlocked with some strong sales of their migraine drug. Having suffered migraines when I was younger, it makes sense to me that sales could surprise to the upside. The new hire looks good for INSM!

    Sentiment: Strong Buy

14.66-0.37(-2.46%)Sep 28 4:00 PMEDT